A5044530307- Dermatology and Skin Diseases
- Cancer Treatment and Pharmacology
- Cancer-related Molecular Pathways
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Breast Cancer Treatment Studies
- Allergic Rhinitis and Sensitization
- Nail Diseases and Treatments
- Neonatal skin health care
- Food Allergy and Anaphylaxis Research
- Monoclonal and Polyclonal Antibodies Research
- Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- Neutropenia and Cancer Infections
- Cancer Genomics and Diagnostics
- Multiple and Secondary Primary Cancers
- Brain Metastases and Treatment
- Global Cancer Incidence and Screening
- Hedgehog Signaling Pathway Studies
- Psoriasis: Treatment and Pathogenesis
- Chronic Lymphocytic Leukemia Research
- Phytochemistry Medicinal Plant Applications
- Contact Dermatitis and Allergies
- Lung Cancer Treatments and Mutations
- Nonmelanoma Skin Cancer Studies
Instituto do Câncer do Estado de São Paulo
2012-2024
Universidade de São Paulo
2012-2024
D’Or Institute for Research and Education
2023-2024
National University College
2022
Universidad Europea
2022
Ulsan College
2022
University of Hong Kong
2022
Chinese Academy of Medical Sciences & Peking Union Medical College
2022
University of Ulsan
2022
National Yang Ming Chiao Tung University
2022
Trastuzumab emtansine is the current standard treatment for patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer whose disease progresses after a combination of anti-HER2 antibodies and taxane.We conducted phase 3, multicenter, open-label, randomized trial to compare efficacy safety trastuzumab deruxtecan (a HER2 antibody-drug conjugate) those in HER2-positive previously treated taxane. The primary end point was progression-free survival (as...
•43/261 patients randomized to T-DXd and 39/263 T-DM1 had clinically inactive BMs at baseline.•For with BMs, median (95%CI) PFS was 15.0 (12.5-22.2) months for vs 3.0 (95% CI, 2.8-5.8) T-DM1.•For confirmed systemic ORR 67.4% versus 20.5% T-DM1.•Intracranial 65.7% 34.3% T-DM1.•Patients HER2+ mBC without achieved greater benefit from treatment T-DM1. BackgroundDESTINY-Breast03 is a randomized, multicenter, open-label, phase III study of trastuzumab deruxtecan (T-DXd) emtansine (T-DM1) in human...
Abstract Background: T-DXd is a HER2-targeting antibody-drug conjugate approved for the treatment of pts with advanced HER2+ mBC based on DESTINY-Breast01 study (NCT03248492). DESTINY-Breast03 (NCT03529110) isa randomized, multicenter, open-label, phase 3 assessing efficacy and safety vs. T-DM1 in previously treated trastuzumab taxane. In primary analysis, demonstrated clinically meaningful statistically significant improvement PFS (Corteset al, ESMO 2021). this exploratory we provide...
Background: The incidence and prevalence of neuroendocrine neoplasms (NEN) are rising. In view continuously improving imaging techniques, more than half the patients present with distant metastases at initial diagnosis. An advanced disease stage negatively correlates 5-year survival rate. IV disease, bone (BM) frequent, yet knowledge concerning their clinical or prognostic relevance is rare. This study presents a single-center experience on frequency management BM in gastroenteropancreatic...
Background In North America and Europe, return‐to‐work (RTW) rates vary among breast cancer (BC) survivors, from 24% to 66% 53% 82% at 6 36 months after diagnosis, respectively. To date, there is a lack of data on RTW BC diagnosis in Latin America. Therefore, the primary objectives this study were define 12 24 identify factors associated with population. Methods total, 125 employed women single institution newly diagnosed interviewed by telephone 6, 12, diagnosis. Those who had inoperable or...
T-DXd, an approved therapy for multiple cancers, carries a risk of interstitial lung disease/pneumonitis (ILD) which may have fatal outcomes if not appropriately identified and managed. Management guidelines require interrupting T-DXd all ILD grades, even asymptomatic, but patients (pts) with Gr 1 be retreated upon complete radiographic recovery. In this retrospective analysis trials, we examined RTx duration recurrence (rILD). Data were pooled from 9 clinical trials pts HER2-altered breast,...
Abstract Background Atopic dermatitis ( AD ) is a skin manifestation of atopy caused by hyperreactivity to various antigens. Studies have shown that 60–100% patients with this condition present colonization S taphylococcus aureus . Given increasing rates antimicrobial resistance, the sensitivity antimicrobials colonizing atopic has been investigated. Cross‐sectional studies worldwide suggest prevalence methicillin‐resistant infection MRSA in population varies from 0% 30.8%. Objectives The...
as espécies de malassezia mais prevalentes nos pacientes com pitiríase versicolor.
FUNDAMENTOS: O prurido é um sintoma freqüente nos pacientes em hemodiálise. Tem etiologia não totalmente esclarecida e difícil manejo, o que piora de modo considerável a qualidade vida dos doentes. OBJETIVOS: Avaliar grau sua influência na renais crônicos MÉTODOS: Estudo transversal com hemodiálise no Complexo Hospitalar Santa Casa Porto Alegre, apresentassem sem outras dermatoses. Utilizou-se escala análoga visual para mensuração do questionário Índice Qualidade Vida Dermatologia....
Neoadjuvant chemotherapy has practical and theoretical advantages over adjuvant strategy in breast cancer (BC) management. Moreover, metronomic delivery a more favorable toxicity profile. The present study examined the feasibility of neoadjuvant two cohorts [HER2+ (TraQme) HER2- (TAME)] locally advanced BC. Twenty patients were prospectively enrolled (TraQme, n=9; TAME, n=11). Both received weekly paclitaxel at 100 mg/m(2) during 8 weeks followed by doxorubicin 24 for 9 combination with oral...
Metronomic therapy has been gaining importance in the neoadjuvant setting of breast cancer treatment. Its clinical benefits may involve antiangiogenic machinery. Cancer cells induce angiogenesis to support tumor growth by secreting factors, such as vascular endothelial factor (VEGF). In cancer, Trastuzumab (TZM) based treatment is key and believed reduce diameter volume blood vessels well permeability. Here we investigated serum levels angiogenic factors VEGF MCSF patients receiving...
Trastuzumab improves the survival of patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC). The incidence and long-term impact trastuzumab-related cardiotoxicity in community setting is great clinical importance.Patients HER2-positive BC treated (neo)adjuvant trastuzumab were retrospectively evaluated. Cardiotoxicity was defined as cardiac death or absolute decrease left ventricular ejection fraction at least 10% to a value less than 50%, symptomatic heart...
FUNDAMENTOS: Pacientes portadores de dermatite atópica apresentam freqüentemente níveis séricos elevados IgE, e o prurido é uma das manifestações cardinais da doença. OBJETIVOS: Descrever as características do nos pacientes com (DA) correlacionar a gravidade eczema os plasmáticos imunoglobulina E (IgE). MÉTODOS: Os atendidos no Serviço Dermatologia Hospital Clínicas Porto Alegre Serviços Pediatria Universidade Luterana Brasil responderam um questionário sobre sintomas deles foi coletado...
Abstract Background: The HER2-low status has gained significance as a target for HER2-directed antibody drug conjugates in breast cancer. It is observed approximately 60% of hormone receptor-positive (HR+) tumors and 30% receptor-negative (HR-) tumors. Some studies suggest that the by itself does not influence tumor biology or prognosis. Breast cancer context Li-Fraumeni (LFS) syndrome been characterized an enrichment HER2-positive (HER2+, defined +3 immunohistochemistry [IHQ] +2 IHQ with...
Breast cancer (BC) is the most common type of in premenopausal women with germline TP53 pathogenic variants (mTP53) (Li Fraumeni syndrome - LFS). However, little known about BC prognosis these patients. This study analyzed BC-related oncologic outcomes patients LFS.We evaluated a cohort LFS comparison control no variant hereditary panel. The primary endpoint was recurrence-free survival (RFS). Due to risk second malignancies LFS, only locoregional and distant recurrences were considered...
Abstract Background: Management of metastatic breast cancer (mBC) in elderly patients (pts) faces some challenges since pts are frail or have functionality impairment, with higher risk severe adverse events from oncologic therapy. We aimed to assess the treatment patterns for MBC and evaluate factors associated outcomes this population. Methods: This retrospective study evaluated 70 years older mBC treated a tertiary center 2009 2022. Charlson index (ChI) was used measure comorbidities....
122 Background: Paclitaxel is one of the most active drugs in BC and weekly administration has been shown more effective better. GEICAM9906 was a phase III trial that demonstrated effectiveness safety pragmatic dose-dense schedule 100mg/m 2 paclitaxel given over 8 consecutive weeks (w), without G-CSF support. This adopted at our institution 2009 for HER2 negative disease herein we present first off-trial experience also compare its profile with historical cohort pts treated conventional...